logo
Plus   Neg
Share
Email

Istesso's Phase 2a Study On Rheumatoid Arthritis Meets Primary Objective

IP Group plc's (IPO.L) portfolio company Istesso Limited said that Phase 2a study of its investigational drug MBS2320, for the treatment of rheumatoid arthritis, met primary objective, and was generally well-tolerated with no drug-related serious adverse events.

In the secondary objectives, there was evidence of clinical benefit as assessed by the American College of Rheumatology 20% response and Disease Activity Score.

IP Group holds a direct undiluted beneficial stake of 56.4% in Istesso.

Separately, IP Group said that portfolio company Ceres Power Holdings and Doosan signed a collaboration and licensing agreement to jointly develop SOFC distributed power systems initially targeted at the Korean commercial building market.

The 8 million pounds agreement includes licencing, technology transfer and engineering services. The agreement. The agreement is more than two years.

Doosan will take a system-level licence of Ceres' proprietary SteelCell SOFC technology to develop a low carbon 5-20kW power system.

IP Group currently holds a direct undiluted beneficial stake of 18.8% in Ceres.

Ceres said today that it and Doosan intend to explore an expansion of the collaboration to access broader applications within South Korea and internationally as well as the potential to broaden the collaboration to include manufacturing.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>